Hantz Financial Services Inc. Sells 1,055 Shares of Sanofi (NASDAQ:SNY)

Hantz Financial Services Inc. trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,904 shares of the company’s stock after selling 1,055 shares during the period. Hantz Financial Services Inc.’s holdings in Sanofi were worth $2,359,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors increased its stake in shares of Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares during the period. Geode Capital Management LLC lifted its holdings in Sanofi by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after purchasing an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the period. Finally, GFS Advisors LLC grew its position in shares of Sanofi by 1,017.9% during the 3rd quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after purchasing an additional 11,655 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Sanofi Price Performance

SNY stock opened at $54.15 on Friday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market cap of $137.42 billion, a price-to-earnings ratio of 27.63, a P/E/G ratio of 1.19 and a beta of 0.57. The company has a 50 day simple moving average of $49.12 and a 200 day simple moving average of $52.24.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Research analysts anticipate that Sanofi will post 3.82 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.